P36.03 Identification of Immune-Related lncRNA Clusters and Prognostic Effects for Lung Adenocarcinoma Patients

Abstract

was (11%, 20/181) vs. (6.6%, 28/426), p¼ 0.066. Median age was 70 years (range 48-90). Patients presented with advanced (80%) and locally advanced disease (16%). There were 21 women, 30 light smokers (<1pack/day), 18 heavy smokers (>1pack/day) and 4 never smokers. Most patients had adenocarcinoma histology (82.7%), while 15.4% displayed squamous cell carcinoma. Most common co-occurring mutations were KRAS (36/52), TP53 (23/52), and STK11 (17/52). Of twenty-one patients with available PDL1 testing, the majority were PDL1 negative (16/21), and a positive PDL1 expression >1% was seen in 5 patients. There were 12 patients with intermediate and 8 patients with high tumor mutation burden. Median PFS for patients treated with platinum-based chemotherapy (n¼21), chemoimmunotherapy (n¼8) and immunotherapy (n¼4) was 4.6, 2.9 and 2.0 months, respectively. Median OS for patients with KEAP1/NRF2 mutations was 16.6 months for all patients. Median OS was 20 months for Hispanics and 15.4 months for NHWs. (p¼0.99). Conclusion: KEAP1/NRF2 mutations portend poor prognosis and treatment resistance for both Hispanics and NHWs in this cohort. There was no statistical difference in prevalence of KEAP/NRF2 mutations and median overall survival for Hispanics when compared to NHWs with KEAP1/NRF2 mutations.